GlaxoSmithKline Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . GlaxoSmithKline PLC ADR
GSK Stock  USD 59.52  0.84  1.39%   
Analyzing historical trends in various income statement and balance sheet accounts from GlaxoSmithKline PLC's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlaxoSmithKline PLC's valuation are summarized below:
Gross Profit
23.7 B
Profit Margin
0.175
Market Capitalization
119.4 B
Enterprise Value Revenue
3.098
Revenue
32.7 B
There are currently one hundred twenty fundamental trends for GlaxoSmithKline PLC ADR that can be evaluated and compared over time across competitors. We recommend to confirm GlaxoSmithKline PLC's regular fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 40.8 B. The Enterprise Value is projected to slide to about 44.2 B

GlaxoSmithKline PLC Total Revenue

20.14 Billion

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 B, Interest Expense of 501.9 M or Total Revenue of 20.1 B, as well as many indicators such as Price To Sales Ratio of 2.15, Dividend Yield of 0.039 or PTB Ratio of 4.29. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
Build AI portfolio with GlaxoSmithKline Stock
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

GlaxoSmithKline PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets37.2 B61 B59.4 B
Slightly volatile
Short and Long Term Debt Total12.3 B17.7 B20.6 B
Slightly volatile
Other Current Liabilities2.8 B3 B9.4 B
Slightly volatile
Total Current Liabilities12.6 B21.4 B19.8 B
Slightly volatile
Property Plant And Equipment Net7.7 B10 B10.2 B
Slightly volatile
Net Debt9.3 B14.3 B16.1 B
Slightly volatile
Accounts Payable16.1 B15.4 B7.2 B
Slightly volatile
Cash3 B3.4 B4.5 B
Very volatile
Non Current Assets Total24.3 B43.5 B41.9 B
Slightly volatile
Cash And Short Term Investments4.1 B3.4 B5.1 B
Pretty Stable
Net Receivables4.7 B7.7 B6.3 B
Slightly volatile
Common Stock Shares Outstanding1.7 B2.1 B1.9 B
Pretty Stable
Short Term Investments8.5 M9 M507.8 M
Pretty Stable
Liabilities And Stockholders Equity37.2 B61 B59.4 B
Slightly volatile
Non Current Liabilities Total16.1 B23.7 B28 B
Slightly volatile
Inventory3.3 B5.9 B5.2 B
Slightly volatile
Other Current Assets399.2 M420.3 M2.2 B
Slightly volatile
Other Stockholder Equity5.1 B4.8 B3.9 B
Slightly volatile
Total Liabilities28.7 B45 B47.9 B
Slightly volatile
Property Plant And Equipment Gross24.8 B23.6 B12.3 B
Slightly volatile
Total Current Assets12.9 B17.5 B17.5 B
Slightly volatile
Capital Stock1.3 B1.6 B1.3 B
Slightly volatile
Short Term Debt2.4 B3 B3.6 B
Pretty Stable
Common Stock1.3 B1.3 B1.4 B
Slightly volatile
Intangible Assets10.9 B16.7 B18 B
Slightly volatile
Other Liabilities14.2 B11.7 B16.9 B
Very volatile
Long Term Debt17.4 B15.8 B17.9 B
Very volatile
Good Will6 B7 B6.9 B
Slightly volatile
Property Plant Equipment9.6 B9.1 B11.2 B
Slightly volatile
Other Assets5.6 B8.8 B5.5 B
Slightly volatile
Long Term Investments77.6 B73.9 B37.6 B
Slightly volatile
Short and Long Term Debt1.9 B2 B7.1 B
Slightly volatile
Additional Paid In Capital3.4 B4 B3.1 B
Slightly volatile
Long Term Debt Total19.7 B16.8 B17.2 B
Slightly volatile
Capital Surpluse3.5 B4 B3.2 B
Slightly volatile
Net Invested Capital21.4 B26.6 B22.4 B
Slightly volatile
Cash And Equivalents2.3 B2.5 B3.4 B
Slightly volatile

GlaxoSmithKline PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.9 B3.7 B2 B
Slightly volatile
Interest Expense501.9 M685.6 M704.8 M
Pretty Stable
Total Revenue20.1 B32 B26.1 B
Slightly volatile
Gross Profit14.8 B23.2 B17.9 B
Slightly volatile
Other Operating Expenses15.5 B24.9 B20.5 B
Slightly volatile
Operating Income4.8 B7 B5.6 B
Very volatile
EBIT5 B7.9 B5.8 B
Very volatile
Research Development7.7 B7.3 B4.6 B
Slightly volatile
EBITDA6.2 B11.6 B7.7 B
Pretty Stable
Total Operating Expenses10.1 B16.2 B12.3 B
Slightly volatile
Income Before Tax4.7 B7.2 B5.1 B
Very volatile
Net Income3.7 B5.6 B4.7 B
Pretty Stable
Income Tax Expense1.1 B1.1 B940.7 M
Slightly volatile
Selling General Administrative9.6 B9 B8.8 B
Slightly volatile
Cost Of Revenue7.6 B8.8 B8.4 B
Slightly volatile
Net Income Applicable To Common Shares5.1 B5.7 B5.7 B
Pretty Stable
Selling And Marketing Expenses317.2 M333.9 M1.1 B
Slightly volatile
Net Income From Continuing Ops2.5 B2.7 B9.1 B
Pretty Stable
Tax Provision666.8 M1.1 B1.2 B
Slightly volatile
Interest Income340 M531 M474.1 M
Slightly volatile
Reconciled Depreciation2.4 B2.9 B2.1 B
Slightly volatile

GlaxoSmithKline PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow3.5 B5.8 B4.4 B
Slightly volatile
Begin Period Cash Flow2.3 B3.6 B4.1 B
Pretty Stable
Depreciation3.9 B3.7 B2.1 B
Slightly volatile
Capital Expenditures1.6 B1.3 B1.9 B
Slightly volatile
Total Cash From Operating Activities5.1 B7.1 B6.3 B
Slightly volatile
Net Income4.7 B5.6 B4.5 B
Pretty Stable
End Period Cash Flow2.2 B3.4 B3.9 B
Pretty Stable
Stock Based Compensation338 M395.6 M321.9 M
Slightly volatile
Change To Liabilities596.5 M568.1 M296.3 M
Slightly volatile
Issuance Of Capital Stock26.3 M18 M51 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.152.26252.6674
Slightly volatile
Dividend Yield0.0390.03470.058
Pretty Stable
Days Sales Outstanding86.5686.694178.5699
Slightly volatile
Book Value Per Share4.153.95532.7407
Slightly volatile
Free Cash Flow Yield0.04380.08060.0717
Slightly volatile
Operating Cash Flow Per Share1.891.80281.6292
Slightly volatile
Stock Based Compensation To Revenue0.00860.00990.0108
Pretty Stable
Capex To Depreciation0.340.35681.1271
Slightly volatile
EV To Sales2.572.7013.1787
Slightly volatile
Free Cash Flow Per Share1.541.471.1331
Slightly volatile
ROIC0.230.14250.1511
Slightly volatile
Inventory Turnover2.051.5141.7836
Very volatile
Net Income Per Share1.481.4111.2302
Slightly volatile
Days Of Inventory On Hand162241208
Very volatile
Payables Turnover0.550.58312.2917
Slightly volatile
Sales General And Administrative To Revenue0.460.410.3774
Pretty Stable
Research And Ddevelopement To Revenue0.240.22980.1501
Slightly volatile
Capex To Revenue0.08130.04130.0788
Pretty Stable
Cash Per Share0.690.84081.1822
Very volatile
POCF Ratio9.6110.120612.4045
Slightly volatile
Interest Coverage9.7210.226813.8206
Slightly volatile
Payout Ratio0.810.44861.0988
Pretty Stable
Capex To Operating Cash Flow0.180.18460.3604
Slightly volatile
PFCF Ratio11.7912.4115252
Slightly volatile
Days Payables Outstanding657626243
Pretty Stable
Income Quality1.021.27761.7282
Very volatile
EV To Operating Cash Flow11.4812.081814.7774
Slightly volatile
PE Ratio12.2812.930518.9235
Slightly volatile
Return On Tangible Assets0.190.1530.1533
Very volatile
EV To Free Cash Flow14.0814.8167263
Slightly volatile
Earnings Yield0.04820.07730.0804
Pretty Stable
Intangibles To Total Assets0.410.38890.3719
Slightly volatile
Net Debt To EBITDA0.941.20531.8707
Pretty Stable
Current Ratio1.470.81861.0187
Slightly volatile
Receivables Turnover4.04.21024.7023
Slightly volatile
Graham Number11.911.3297.7756
Slightly volatile
Capex Per Share0.280.33280.492
Slightly volatile
Revenue Per Share8.478.06397.0416
Slightly volatile
Interest Debt Per Share4.774.54735.065
Slightly volatile
Debt To Assets0.230.28990.3314
Pretty Stable
Enterprise Value Over EBITDA7.057.425210.4633
Slightly volatile
Short Term Coverage Ratios2.262.42462.0059
Slightly volatile
Price Earnings Ratio12.2812.930518.9235
Slightly volatile
Operating Cycle176328264
Slightly volatile
Days Of Payables Outstanding657626243
Pretty Stable
Dividend Payout Ratio0.810.44861.0988
Pretty Stable
Price To Operating Cash Flows Ratio9.6110.120612.4045
Slightly volatile
Price To Free Cash Flows Ratio11.7912.4115252
Slightly volatile
Pretax Profit Margin0.30.22660.2167
Slightly volatile
Ebt Per Ebit1.031.03240.8784
Pretty Stable
Operating Profit Margin0.320.21950.2508
Slightly volatile
Effective Tax Rate0.290.15020.2014
Slightly volatile
Long Term Debt To Capitalization0.370.47320.6234
Pretty Stable
Total Debt To Capitalization0.420.51970.6666
Pretty Stable
Return On Capital Employed0.170.18050.2043
Slightly volatile
Ebit Per Revenue0.320.21950.2508
Slightly volatile
Quick Ratio0.510.54160.6974
Slightly volatile
Dividend Paid And Capex Coverage Ratio1.961.86681.2348
Slightly volatile
Net Income Per E B T0.60.77230.8587
Pretty Stable
Cash Ratio0.170.15880.2327
Slightly volatile
Operating Cash Flow Sales Ratio0.170.22360.2235
Pretty Stable
Days Of Inventory Outstanding162241208
Very volatile
Days Of Sales Outstanding86.5686.694178.5699
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.460.81540.6184
Pretty Stable
Cash Flow Coverage Ratios0.570.41210.3624
Pretty Stable
Fixed Asset Turnover2.123.25112.8197
Very volatile
Capital Expenditure Coverage Ratio5.695.41773.3769
Slightly volatile
Price Cash Flow Ratio9.6110.120612.4045
Slightly volatile
Enterprise Value Multiple7.057.425210.4633
Slightly volatile
Debt Ratio0.230.28990.3314
Pretty Stable
Cash Flow To Debt Ratio0.570.41210.3624
Pretty Stable
Price Sales Ratio2.152.26252.6674
Slightly volatile
Return On Assets0.150.09350.1013
Pretty Stable
Asset Turnover0.770.53450.5454
Slightly volatile
Net Profit Margin0.220.1750.1855
Very volatile
Gross Profit Margin0.790.72540.6985
Very volatile

GlaxoSmithKline PLC Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.8 B46.8 B49.3 B
Pretty Stable
Enterprise Value44.2 B61.1 B63.1 B
Pretty Stable

GlaxoSmithKline Fundamental Market Drivers

Forward Price Earnings22.6757
Cash And Short Term Investments3.4 B

GlaxoSmithKline Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as revenue or net income, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue325.5 M341.7 M
Total Revenue32 B20.1 B
Cost Of Revenue8.8 B7.6 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.41  0.46 
Research And Ddevelopement To Revenue 0.23  0.24 
Capex To Revenue 0.04  0.08 
Revenue Per Share 8.06  8.47 
Ebit Per Revenue 0.22  0.32 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
How To Invest In GlaxoSmithKline
Details
Is GlaxoSmithKline Stock a good investment?
Details
What is GlaxoSmithKline PLC's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.551
Dividend Share
0.66
Earnings Share
3.78
Revenue Per Share
16.128
Quarterly Revenue Growth
0.062
Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY